Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Chikara Ogawa, Joji Tani, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Ito, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Hidenori Toyoda, Hideko Ohama, Kazuhiro Nozui, Akemi Tsutsui, Takuya Nagano, Norio Ito, Korenobu Hayama, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Kojiro Michitaka, Yoichi Hiasa, and Masatoshi Kudo; On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular-carcinoma experts from 48 clinics in Japan)

1Gastroenterology Center, Ehime Prefectural Central Hospital, Ehime, Japan; 2Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Gifu, Japan; 3Department of Internal Medicine, Himeji Red Cross Hospital, Hyogo, Japan; 4Department of Gastroenterology and Hepatology, Takamatsu Red Cross Hospital, Takamatsu, Japan; 5Department of Gastroenterology and Hepatology, Kagawa university, Kagawa, Japan; 6Department of Gastroenterology, Osaka Medical College, Osaka, Japan; 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan; 8Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Ehime, Japan; 9Center of Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan; 10Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan; 11Department of Gastroenterology, Kagawa Prefectural Central Hospital, Takamatsu, Japan; 12Department of Gastroenterology, Okayama City Hospital, Okayama, Japan; 13Department of Gastroenterology, Asahi General Hospital, Asahi, Japan; 14Department of Gastroenterology, Toyama University Hospital, Toyama, Japan; 15Division of Gastroenterology and Hepatology, Otakanomori Hospital, Kashiwa, Japan; 16Department of Gastroenterology, Tokushima Prefectural Central Hospital, Tokushima, Japan; 17Hepato-biliary Center, Matsuyama Red Cross Hospital, Matsuyama, Japan; 18Department of Hepatology, Hamamatsu University School of Medicine, Hamamatsu, Japan; 19Department of Gastroenterology, Kindai University, Osaka, Japan

Submitted: 2 March 2020; Revised: 5 June 2020; Accepted: 12 June 2020

© The Author(s) 2020. Published by Oxford University Press and Sixth Affiliated Hospital of Sun Yat-sen University

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Background: Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment.

Methods: Of 385 patients with u-HCC and treated with lenvatinib at 16 different institutions in Japan between May 2018 and January 2020, 28 who received ramucirumab as the next treatment were enrolled and therapeutic responses were evaluated in a retrospective manner.

Results: The median age of the 28 patients given ramucirumab was 70 years and the median albumin-bilirubin score was –2.19. Of the 28 patients, 23 were male, 21 were classified as Child–Pugh A and 7 as Child–Pugh B, and 25 were Barcelona Clinic Liver Cancer Stage C. Ramucirumab was given as second-line therapy in 14, third-line in 9, and fourth-line in 5. Therapeutic response was obtained in only 26 patients; the objective response rate was 3.8% (1/26) and the disease-control rate was 42.3% (11/26), with a median period to progression of 2.0 months. The reasons for discontinuation of ramucirumab were progression of disease in 16 and Grade 3 adverse events (gastrointestinal bleeding, ascites) in 2.

Conclusions: The anticipated therapeutic efficacy of ramucirumab for post-progression treatment following lenvatinib was not seen in our early experience.

Key words: hepatocellular carcinoma; ramucirumab; lenvatinib; sorafenib

Introduction

Recently, several different systemic chemotherapy regimens that use a tyrosine kinase inhibitor (TKI) and/or molecular-targeting agent (MTA) for unresectable hepatocellular carcinoma (u-HCC) have become available. Sorafenib was developed as a first-line TKI [1, 2], after which regorafenib was introduced as a second-line drug in 2017 [3]. Nevertheless, a remaining important unmet need is the lack of therapeutic options for u-HCC patients who show sorafenib intolerance or regorafenib failure. Although lenvatinib was developed as a first-line TKI drug [4], it is given not only as a first-, but also as a second- and third-line treatment option in Japan [5–9].

In 2019, ramucirumab became available as a new second-line drug. Ramucirumab is a recombinant monoclonal human immunoglobulin IgG1 antibody-specific inhibitor of vascular endothelial growth factor 2 (VEGFR-2), which is an important primary driving factor for both physiological and pathological angiogenesis. Although no survival benefit was proved in the REACH trial, sub-analysis of patients with an alpha-fetoprotein (AFP) level >400 ng/mL revealed improved survival [10], thus the REACH-2 trial was planned and performed [11]. The REACH-2 trial demonstrated its clinical efficacy following sorafenib treatment as compared with a placebo [11]. However, lack of an established post-progression treatment option for patients with lenvatinib failure has become evident. In the present study, we aimed to elucidate the clinical features of post-progression systemic chemotherapy drugs, especially ramucirumab, for follow-up lenvatinib failure.

Materials and methods

Sources of patients

A total of 385 patients with u-HCC were treated with lenvatinib at specific institutions in Japan (Ehime Prefectural Hospital, Ogaki Municipal Hospital, Himeji Red Cross Hospital, Takamatsu Red Cross Hospital, Kagawa University, Osaka Medical School, Nippon Medical School, Ehime University Graduate School of Medicine, Teine Keijinkai Hospital, Saiseikai Niigata Hospital, Kagawa Prefectural Central Hospital, Okayama City Hospital, Asahi General Hospital, Toyama University Hospital, Otakanomori Hospital, Tokushima Prefectural Central Hospital, Matsuyma Red Cross Hospital, and Hamamatsu University School of Medicine) between May 2018 and January 2020. Among them, 28 who received ramucirumab as post-progression treatment and showed therapeutic response were evaluated in a retrospective manner.

Basal hepatic disease related to HCC

HCC due to hepatitis C virus (HCV) was judged when the anti-HCV was positive, whereas HCC due to hepatitis B virus (HBV) was judged when the hepatitis B virus surface antigen (HBsAg) was positive.

Methods for hepatic reserve function and therapeutic-response assessments

Child–Pugh classification [12] and albumin-bilirubin (ALBI) grade were used for assessment of the hepatic reserve function. The ALBI grade was calculated with serum-albumin and total-bilirubin values using the following formula: ALBI score = [log10 bilirubin (µmol/L) × 0.66] + [Albumin (g/L) × −0.085], with the result defined by the following scores: ≤−2.60, Grade 1; >−2.60 to ≤−1.39, Grade 2; and >−1.39, Grade 3 [13–15]. To perform more detailed evaluations of patients with the middle ALBI grade of 2, we used a revised grading system consisting of four levels that included sub-grading for the middle grade of 2 (2a and 2b) based on an ALBI score of −2.27 as the cut-off, which was previously developed based on the value for indocyanine green retention after 15 min (ICG-R15) of 30% [16, 17]. Local physicians at each participating hospital independently evaluated HCC status using dynamic computed tomography (dy-CT) and/or magnetic resonance imaging (MRI) procedures performed at 4 or 8 weeks after the introduction of post-progression treatment (sorafenib or ramucirumab) based on the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1 [18], when possible.
HCC diagnosis and treatment

Based on an increasing course of AFP, as well as dy-CT [19], MRI [20, 21], contrast-enhanced ultrasonography with perflubutane (Sonazoid®, Daichi Sankyo Co., Ltd, Tokyo, Japan) [22, 23], and/or pathological findings, HCC was diagnosed. We used Barcelona Clinic Liver Cancer (BCLC) stage [24] and tumor node metastasis (TNM) stage, determined as previously reported in a study for the TNM staging of HCC conducted by the Liver Cancer Study Group of Japan (LCSGJ) 6th edition [25] (TNM-LCSGJ), to evaluate tumor progression. Written informed consent for MTA treatment was obtained from all of the patients. The protocol used in the present study was approved by the Institutional Ethics Committee of Ehime Prefectural Central Hospital (IRB No. 30-66).

Ramucirumab treatment and assessment of adverse events

Ramucirumab was given as an intravenous injection at a dose of 8 mg/kg once every 2 weeks. According to the guidelines for the administration of ramucirumab, the dose should be reduced or the treatment should be interrupted when a patient develops any Grade 3 or more severe adverse event (AE) or if any unacceptable Grade 2 drug-related AE occurs. AEs were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 [26]. The worst grade for each AE during the present observation period was recorded. If a drug-related AE occurred, dose reduction or temporary interruption was maintained until the symptom was resolved to Grade 1 or 2, according to the guidelines provided by the manufacturer.

Statistical analysis

Statistical analyses were performed using the Kaplan–Meier method or a log-rank test. A P-value <0.05 was considered statistically significant. Easy R (EZR), version 1.29 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [27], a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria), was used for all statistical analyses.

Results

Patient characteristics

Among the 385 patients treated with lenvatinib during the study period, 28 who subsequently received ramucirumab as post-progression treatment were analysed. Their median age was 70 years and 23 were male. Six were diagnosed pathologically and the others were using the diagnostic algorithm for HCC [24]. No patient had any known past history of chronic hepatic failure, chronic respiratory diseases, or chronic renal failure. Twenty-one were classified as Child–Pugh A and seven as Child–Pugh B, and the median ALBI score was 2.19. BCLC stage C was noted in 25. All had undergone lenvatinib treatment, with ramucirumab used as second-line treatment in 14, as third-line in 9, and as fourth-line in 5 (Table 1).

Therapeutic efficacy

Among these 28 patients, therapeutic response according to RECIST version 1.1 was obtained in 26. Partial response (PR) was observed in only 1 and stable disease (SD) was noted in 10, whereas progressive disease (PD) was seen in 15, with an objective response rate (ORR) of 3.8% (1/26) and a disease-control rate (DCR) of 42.3% (11/26) (Table 2). Until the end of January 2020, ramucirumab treatment was stopped in 18; the major reasons for discontinuation were PD in 16 and AE (Grade 3) in 2 (gastrointestinal bleeding, ascites). The median time to progression (TTP) was 2 months [95% confidential interval (CI), 1.4–3.2 months] (Figure 1A). There were no significant differences for TTP and DCR between patients who only received lenvatinib and those treated with multiple MTA drugs, including lenvatinib before ramucirumab (1.8 vs 2.1 months, P = 0.789) (38.5% vs 46.1%, P = 1.0). TTP was also not significantly different between Child–Pugh class A and B classification (2.0 vs 2.1 months, P = 0.986). At the end of the study period, more than half of the patients had survived, thus the median survival time after introducing ramucirumab and the initial MTA drug were not reached (Figure 1B and C).

Table 1. Clinical features of 28 unresectable hepatocellular carcinoma patients treated with ramucirumab

| Factor                        | Value |
|-------------------------------|-------|
| Age, years#                  | 70 (60–76) |
| Gender, male:female           | 23:5 |
| Etiology, HBV:hepatitis C virus:others | 8:7:4:9 |
| BMI, kg/m²#                   | 23.2 (21.1–24.3) |
| EOGF PS, 0:1                  | 18:10 |
| Platelet, x 10⁴/µL#          | 13.9 (11.2–19.2) |
| AST, IU/L#                    | 51 (36–68) |
| ALT, IU/L#                    | 32 (20–57) |
| Total bilirubin, mg/dL#       | 0.9 (0.7–1.2) |
| Albumin, g/dL#                | 3.5 (3.3–3.7) |
| Prothrombin time, %a          | 91 (82–97) |
| NH3, µg/dL#                   | 50 (36–60) |
| Child–Pugh score, 5:6:7:8:9   | 9:12:6:0:1 |
| Modified ALBI, 1:2:2b         | 2:9:17 |
| ALBI score#                   | –2.19 (–2.36 to –1.96) |
| Positive for MVI (n = 10)⁵     | 7:3:2 |
| Positive for EHM (n = 18)⁶     | 13:5:5:2 |
| TNM stage of LCSGJ 6th, III:IVa:IVb | 4:6:18 |
| BCLC stage, B:C               | 3:2:5 |
| AFP, ng/mL#                   | 3,019 (989–8,189) |
| History of MTAs⁵, LEN:SOR:REG | 28:14:5 |
| Previous treatment, LEN:SOR:TACE | 22:5:1 |
| Use of ramucirumab, 2nd:3rd:4th-line | 14:9:5 |

# a Median (interquartile range). b There are duplicate cases; HCV, hepatitis C virus; HBV, hepatitis B virus; others, patients without viral infection or alcohol abuse; BMI, body mass index; EOGF PS, Eastern Cooperative Oncology Group performance status; AST, aspartate transaminase; ALT, alanine aminotransferase; ALBI, albumin-bilirubin; MVI, main vessel invasion; Vp2, tumor invasion to secondary portal branch; Vp4, tumor invasion to main portal branch; Vv2, tumor invasion to hepatic vein trunk; EHM, extra-hepatic metastasis; LN, lymph node; TNM-LCSGJ 6th, tumor node metastasis stage by Liver Cancer Study Group of Japan, 6th edition; BCLC, Barcelona Clinic Liver Cancer stage; AFP, alpha-fetoprotein; MTA, molecular-targeting agent; LEN, lenvatinib; SOR, sorafenib; REG, regorafenib; TACE, transcatheter arterial chemo-embolization.

Adverse events

Grade 3 AEs noted in the 28 patients were hepatic coma (n = 1; 3.6%), gastrointestinal bleeding (duodenal ulcer: n = 1; 3.6%), ascites (n = 1; 3.6%), fatigue and appetite loss (n = 1; 3.6%), and fever (n = 1; 3.6%), whereas Grade 1/2 AEs included ascites or pretibial edema (n = 6; 21.4%), fatigue and appetite loss (n = 5; 17.8%), diarrhea (n = 3; 10.7%), and fever (n = 1; 3.6%) (Table 3).
In the present analysis, the ORR and DCR for ramucirumab as post-progression treatment following lenvatinib were 3.8% and 42.3%, respectively. In previous reports [5–9], the therapeutic efficacy of lenvatinib did not show a significant difference between u-HCC patients with or without a past history of MTA treatment. A similar result was observed in the present study. There were no significant differences for either TTP or DCR between patients who received only lenvatinib and those who were treated with multiple MTA drugs, including lenvatinib, prior to ramucirumab.

Few reports regarding the therapeutic efficacy of ramucirumab given following lenvatinib as post-progression have been presented. In the REACH-2 trial, the ORR and DCR for ramucirumab as a second-line treatment after sorafenib [11] were superior as compared with those in the present study. Recently, Kuzuya et al. [28] reported a high DCR (80%) with ramucirumab in 10 patients with unresectable HCC, of whom 8 (80%) were treated with ramucirumab as second-line treatment following lenvatinib. In contrast, ramucirumab was used as a third- or fourth-line treatment more frequently (50%) in the present study than in that report. Interestingly, in the present cohort, there was no significant difference for DCR between patients who received ramucirumab as second-line and those who received it as third-/fourth-line treatment. Our results suggest that the therapeutic potential of ramucirumab given as post-progression treatment after lenvatinib might be not sufficient.

Abnormal expression of FGF19-FGFR4 has been reported as an oncogenic-driver pathway for HCC [29]. Among the four MTA drugs available in Japan at the time of writing (early 2020), only lenvatinib is known to inhibit FGFR 4 (Table 4). In another study, sorafenib administration did not increase the level of FGF19 from the baseline, whereas the level of FGF19 was significantly increased compared with the baseline in patients given lenvatinib (\( P < 0.001 \)), and the FGF19 level was higher in the patients given lenvatinib than in those given sorafenib at any point during the study period (\( P < 0.05 \)) [30]. FGFR signals via the autocrine loop of FGFR4 corresponding to FGF19 have been reported [31–34] and an elevated level of FGF19 in serum is thought to be a result of the suppression of FGFR4 expression by lenvatinib. When therapeutic failure is observed in patients receiving lenvatinib, FGFR4 expression is presumed to exist, thus HCC may have acquired resistance to VEGF signal suppression at the time of lenvatinib failure. As a result, it is expected that not only ramucirumab, but also other MTAs (sorafenib and regorafenib), might have a lower therapeutic effect than expected in patients with lenvatinib failure. Although lenvatinib was developed as a first-line agent, it has also been used for late-line treatments in Japan [5–9]. In contrast, sorafenib has not been shown to have potential for post-progression treatment following lenvatinib. In our Child–Pugh A patients, the ORR and DCR for sorafenib given for PD in patients who had received lenvatinib were 0.0% and 16.7%, respectively, whereas those for ramucirumab were 0.0% and 36.8%, respectively (data not shown). Thus, a new
unmet clinical need is now apparent, as there is no established post-progression therapy for patients with lenvatinib failure.

This study has some limitations, including its retrospective nature. In addition, the number of cases analysed was too few to obtain concrete conclusions. We did not examine FGF-19–FGFR4 expression in the present cohort, thus further investigations and accumulation of more records of patients given ramucirumab after failure with lenvatinib are needed. Nevertheless, our findings indicate that the therapeutic efficacy of ramucirumab after failure with lenvatinib might be limited.

In our early experience, the anticipated therapeutic efficacy of ramucirumab given following lenvatinib treatment has not been observed. It is difficult to fully explain our results at this time; determination of the best strategic order of administration of these drugs is an important issue to obtain prognosis improvement in affected patients.

Statement of ethics

The present study protocol was approved by the Institutional Ethics Committee of Ehime Prefectural Central Hospital [IRB No. 30-66]. The research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Authors’ contributions

A.H. and T.K. conceived of the study and participated in its design and coordination. A.H., Ku.T., Ko.T., E.I., K.Kar., H.Oc., Ka.T., M.H., T.A., N.S., T.I., A.T., H.S., T.T., K.N., N.I., K.J., Y.H., K.M., M.I., M.A., K.H., T.N., Y.K., S.F., H.Oh., K.Kaw., S.N., J.T., C.O., and M.K. performed data curation. A.H. performed statistical analyses and interpretation. A.H. and T.K. drafted the text. All authors have read and approved the final version of the manuscript.

Funding

None to declare.

Acknowledgements

None to declare.

Conflicts of interest

Atsushi Hiraoka, MD, PhD: Lecture fees; Bayer, Eisai, Otsuka. Takashi Kumada, MD, PhD: Lecture fees; Eisai. Masatoshi Kudo, MD, PhD: Lecture fees; Bayer, Eisai, MSD, Ajinomoto. Grants; Chugai, Otsuka, Takeda, Taiho, Sumitomo Dainippon, Daiichi Sankyo, MSD, Eisai, Bayer, Abbvie, Medico’s Hirata, Astellas Pharma, Bristol-Myers Squibb. None of the other authors have potential conflicts of interest to declare.

References

1. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–90.
2. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34.
3. Bruix J, Qin S, Merle P et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56–66.
4. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–73.
5. Hiraoka A, Kumada T, Kariyama K et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res 2018;49:111–7.
6. Hiraoka A, Kumada T, Kariyama K et al. Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: multicenter analysis. Cancer Med 2019;8:137–46.
7. Fuchigami A, Imai Y, Uchida Y et al. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. PLoS One 2020;15:e0231427.
8. Sho T, Suda G, Ogawa K et al. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. JGH Open 2020;4:54–60.
9. Takahashi A, Moriguchi M, Seko Y et al. Early tumor shrinkage as a predictive factor for outcomes in hepatocellular carcinoma patients treated with lenvatinib: a multicenter analysis. Cancers 2020;12:754.
10. Zhu AX, Baron AD, Malfertheiner P et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: analysis of REACH trial results by Child-Pugh score. JAMA Oncol 2017;3:235–43.
11. Zhu AX, Finn RS, Galle PR et al. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alphafetoprotein. Lancet Oncol 2019;20:e191.
12. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646–9.
13. Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach: the ALBI grade. J Clin Oncol 2015;33:550–8.

14. Hiraoka A, Kumada T, Michitaka K et al. Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. J Gastroenterol Hepatol 2016;31:1031–6.

15. Hiraoka A, Kumada T, Kudo M et al. Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan Society of Hepatology: a comparison with the liver damage and Child-Pugh classifications. Liver Cancer 2017;6:204–15.

16. Hiraoka A, Michitaka K, Kumada T et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 2017;6:325–36.

17. Hiraoka A, Ichiryu M, Tazuya N et al. Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncol Lett 2010;1:57–61.

18. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228–47.

19. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208–36.

20. Di Martino M, Marin D, Guerrisi A et al. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis. Radiology 2010;256:806–16.

21. Sano K, Ichikawa T, Motosugi U et al. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging. Radiology 2011;261:834–44.

22. Hiraoka A, Ichiryu M, Tazuya N et al. Clinical translation in the treatment of hepatocellular carcinoma following the introduction of contrast-enhanced ultrasonography with Sonazoid. Oncol Lett 2010;1:57–61.

23. Hiraoka A, Hiasa Y, Onji M et al. New contrast enhanced ultrasonography agent: impact of Sonazoid on radiofrequency ablation. J Gastroenterol Hepatol 2011;26:616–8.

24. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14.

25. The Liver Cancer Study Group of Japan. The General Rules For The Clinical And Pathological Study of Primary Liver Cancer, 6th edn. Tokyo: Kanehara, 2015, 26.

26. National Cancer Institute. Protocol development cancer therapy evaluation program. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (29 February 2020, date last accessed).

27. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–8.

28. Kuzuya T, Ishigami M, Ito T et al. Initial experience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma. Anticancer Res 2020;40:2089–93.

29. Raja A, Park I, Haq F et al. FGFR9-FGFR4 signaling in hepatocellular carcinoma. Cells 2019;8:536.

30. Finn RS, Kudo M, Cheng A-L et al. Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]. Ann Oncol 2018;29:viii17–8.

31. Desnoyers LR, Pai R, Ferrando RE et al. Targeting FGFR19 inhibits tumor growth in colon cancer xenograft and FGFR19 transgenic hepatocellular carcinoma models. Oncogene 2008;27:85–97.

32. French DM, Lin BC, Wang M et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012;7:e36713.

33. Hyeon J, Ahn S, Lee JJ et al. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig Dis Sci 2013;58:1916–22.

34. Repana D, Ross P. Targeting FGFR9/FGFR4 pathway: a novel therapeutic strategy for hepatocellular carcinoma. Diseases 2015;3:294–305.